Novartis ribociclib Phase III NATALEE trial meets primary en

Demonstrating clinically meaningful benefit in broad population of patients with early breast cancer Ribociclib plus endocrine therapy (ET) significantly reduced

Related Keywords

California , United States , Philippine , Benguet , Philippines , Norway , Dennisj Slamon , Rosariov Pitargue , Joel Chong , Shreeram Aradhye , University Of California , Translational Research In Oncology , Clinical Translational Research , Akershus University Hospital , Drug Administration , European Commission , Data Monitoring Committee , Global Drug Development , Novartis Institutes For Biomedical Research , Novartis Healthcare Philippines Inc , Los Angeles Jonsson Comprehensive Cancer Center , Novartis , Philippine Society Of Medical Oncology , Astex Pharmaceuticals , Independent Data Monitoring Committee , Translational Research , Executive Director , Chief Medical Officer , Philippine Society , Medical Oncology , Country President , Novartis Healthcare Philippines , Standardized Definitions , Efficacy End Points , Clinical Benefit Scale , United States Food , Novartis Institutes , Biomedical Research ,